Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Contineum Therapeutics
Age
25–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All parts: male volunteers or female volunteers of non-childbearing potential; agree to follow the contraception requirements of the trial, and able to give fully informed written consent.
Part A: normotensive volunteers, deemed healthy on the basis of a clinical history, medical examinations, ECG, vital signs, and laboratory tests of blood and urine.
Part B: volunteers with a diagnosis of PPMS or SPMS by a neurologist, according to the 2017 Revised McDonald Criteria.
Part C: volunteers with a diagnosis of IPF by a pulmonologist, according to the 2018 American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) Clinical Practice Guideline, within 7 years before screening.
You may not be if
Positive tests for hepatitis B and C, human immunodeficiency virus (HIV)
Severe adverse reaction to any drug; sensitivity to trial medication
Drug or alcohol abuse
Smoking or use of tobacco or nicotine-containing products from 7 days before screening, until the final visit
Use of a prescription medicine (except hormone replacement therapy \[HRT\] in women, and medications for participants with PrMS and IPF at the discretion of the investigator), or any substance known to interact with cytochrome p450 (CYP)3A enzymes (including St. John's wort and foodstuffs such as grapefruit juice) during the 28 days before the first dose of PIPE-791
Use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol) during the 7 days before the first dose of PIPE-791, or received vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the 7 days before screening
Participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the 3 months before the baseline PET scan
Vital signs or ECGs outside the acceptable range at screening
Clinically relevant abnormal findings at the screening assessments, including C-SSRS and MRI (Parts A \[brain PET imaging arm\] and B only)
Acute or chronic illness (except PrMS and IPF in Parts B and C, respectively)
Clinically relevant abnormal medical history or concurrent medical condition
Possibility that volunteer will not cooperate
Contraindications to MRI (Parts A \[brain PET imaging arm\] and B only), computed tomography (CT), PET, or arterial cannulation procedures
Significant exposure to research-related radiation or other radiation exposure (exceeding 10 mSv when added to exposure from this study) within the previous 12 months
Clareo Health | PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
